Leiden University Medical Center

The LUMC is a center of medical innovation that aims to improve patient care through scientific research. It trains doctors, specialist care providers and researchers to contribute to this. In addition to general patient care, the LUMC offers specialist treatments that can only be performed in a limited number of medical centers. The LUMC is particularly distinguished as a referral center for complex medical questions that have no ready-made answers. Scientists and doctors work together on a better understanding of diseases and new treatment methods.

Related News

INOVIO REPORTS FDA PARTIAL CLINICAL HOLD FOR PLANNED PHASE 2 / 3 TRIAL OF COVID-19 VACCINE CANDIDATE INO-4800

INOVIO | September 28, 2020

news image

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has notified the company it has additional questions about the company's planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA® 2000 delivery device to be used in the trial. Until the FDA's questions have been satisfac...

Read More

BIOTECH LIFE SCIENCES INITIATES NEW STUDY OF ANTI-AGING FORMULAS IN HELPING COVID-19 POST-VIRAL FATIGUE AND CHRONIC FATIGUE SYNDROME

BioTech Life Sciences | August 06, 2020

news image

BioTech Life Sciences (BioTech – https://btl.science) recently announced it was studying the effects of its proprietary formulas on long-term patient symptoms related to COVID-19 Post-Viral Fatigue (long-haulers) and chronic fatigue syndrome (C.F.S.).The findings will be a part of a larger research study undertaken by the company, and is currently calling for voluntary participants; especially those who suffer from myalgic encephalomyelitis (M.E.), chronic fatigue syndrome, or Post-V...

Read More

INDUSTRY OUTLOOK

BIOMEDICAN ENTERS THE ASTAXANTHIN MARKET THROUGH BIOSYNTHESIS PLATFORM TO TARGET HIGH-VALUE COMPOUND AND DISRUPT THE CURRENT TECHNOLOGIES

BIOMEDICAN | December 03, 2020

news image

BIOMEDICAN, a biotech organization planning patented minimal methods for developing high-value compounds at scale with proprietary yeasts, has entered the Astaxanthin market to diversify products outside of Cannabinoids. This new advancement permits BIOMEDICAN's biosynthesis platform to focus on any high-value compound and fundamentally disturb the current advances. Astaxanthin is a widely used, high-value compound known as a powerful antioxidant and anti-inflammatory. The Ast...

Read More

AKERS BIOSCIENCES AND PREMAS BIOTECH ANNOUNCE PROGRESS IN ITS VACCINE DEVELOPMENT FOR COVID-19

PipelineReview | April 06, 2020

news image

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate. The clone development process has four primary steps including first, the design and synthesis of the genes; second, the selecti...

Read More
news image

INOVIO REPORTS FDA PARTIAL CLINICAL HOLD FOR PLANNED PHASE 2 / 3 TRIAL OF COVID-19 VACCINE CANDIDATE INO-4800

INOVIO | September 28, 2020

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has notified the company it has additional questions about the company's planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA® 2000 delivery device to be used in the trial. Until the FDA's questions have been satisfac...

Read More
news image

BIOTECH LIFE SCIENCES INITIATES NEW STUDY OF ANTI-AGING FORMULAS IN HELPING COVID-19 POST-VIRAL FATIGUE AND CHRONIC FATIGUE SYNDROME

BioTech Life Sciences | August 06, 2020

BioTech Life Sciences (BioTech – https://btl.science) recently announced it was studying the effects of its proprietary formulas on long-term patient symptoms related to COVID-19 Post-Viral Fatigue (long-haulers) and chronic fatigue syndrome (C.F.S.).The findings will be a part of a larger research study undertaken by the company, and is currently calling for voluntary participants; especially those who suffer from myalgic encephalomyelitis (M.E.), chronic fatigue syndrome, or Post-V...

Read More
news image

INDUSTRY OUTLOOK

BIOMEDICAN ENTERS THE ASTAXANTHIN MARKET THROUGH BIOSYNTHESIS PLATFORM TO TARGET HIGH-VALUE COMPOUND AND DISRUPT THE CURRENT TECHNOLOGIES

BIOMEDICAN | December 03, 2020

BIOMEDICAN, a biotech organization planning patented minimal methods for developing high-value compounds at scale with proprietary yeasts, has entered the Astaxanthin market to diversify products outside of Cannabinoids. This new advancement permits BIOMEDICAN's biosynthesis platform to focus on any high-value compound and fundamentally disturb the current advances. Astaxanthin is a widely used, high-value compound known as a powerful antioxidant and anti-inflammatory. The Ast...

Read More
news image

AKERS BIOSCIENCES AND PREMAS BIOTECH ANNOUNCE PROGRESS IN ITS VACCINE DEVELOPMENT FOR COVID-19

PipelineReview | April 06, 2020

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate. The clone development process has four primary steps including first, the design and synthesis of the genes; second, the selecti...

Read More